Literature DB >> 3319600

Prolactinomas.

M L Vance1, M O Thorner.   

Abstract

Prolactin-secreting pituitary tumors are not rare. The diagnosis of a patient with hyperprolactinemia and possible tumor should be carried out in an orderly fashion by first excluding secondary causes. If the patient has pathologic hyperprolactinemia, assessment of pituitary anatomy with a high resolution CT scan (or MRI) should be done. In patients who have a macroadenoma, quantitative visual field examination should be a part of the ophthalmologic examination. The choice of therapy is dependent on the clinical findings, the risks of therapy, and patient preference. Currently, the most effective therapy for a patient with a macroadenoma is medical therapy with a dopamine agonist, but this must be given chronically. Regardless of the therapy selected, these patients must be followed regularly. Once fertility is established, there is usually no contraindication to pregnancy in women who wish to become pregnant.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319600

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  12 in total

Review 1.  Medical management of prolactin-secreting pituitary adenomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

2.  Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.

Authors:  K Kovacs; L Stefaneanu; E Horvath; R V Lloyd; I Lancranjan; M Buchfelder; R Fahlbusch
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

Review 3.  Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm.

Authors:  Avital Perry; Christopher Salvatore Graffeo; Christopher Marcellino; Bruce E Pollock; Nicholas M Wetjen; Fredric B Meyer
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-24

4.  Hyperprolactinemia in Women of Reproductive Age: Etiology, diagnosis, and management.

Authors:  B H Yuen
Journal:  Can Fam Physician       Date:  1992-02       Impact factor: 3.275

5.  Pituitary Adenomas.

Authors:  Grant T. Liu
Journal:  Curr Treat Options Neurol       Date:  2002-07       Impact factor: 3.598

Review 6.  Control of prolactin secretion.

Authors:  G Benker; C Jaspers; G Häusler; D Reinwein
Journal:  Klin Wochenschr       Date:  1990-12-04

Review 7.  Current management of prolactinomas.

Authors:  P Nomikos; M Buchfelder; R Fahlbusch
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

8.  Changes in the Options for Management of Prolactin Secreting Pituitary Adenomas.

Authors:  Sherry L Iuliano; Wenya Linda Bi; Edward R Laws
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-18

9.  Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy.

Authors:  M M Garcia; L P Kapcala
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

Review 10.  Hyperprolactinemia.

Authors:  Jaspreet Chahal; Janet Schlechte
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.